Related Experiment Video
Updated: Dec 23, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
705
Treating the Disease, Not the Symptom: Beyond NSAIDs
Robert R Bowers1, Joe R Delaney1, Demetri D Spyropoulos2
1Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, Charleston, SC 29425, USA.
Trends in Cancer
|April 30, 2020
Summary
Reducing inflammation is key for cancer prevention. This study examines limiting exposure to pro-inflammatory chemicals for better health, moving beyond traditional pharmaceutical approaches.
Area of Science:
- Oncology
- Inflammation Research
- Toxicology
Background:
- Inflammation is a critical factor in cancer development and progression.
- Pharmaceutical interventions are the traditional approach to managing inflammation.
- There is a growing need to explore alternative strategies for inflammation mitigation.
Purpose of the Study:
- To critically evaluate the concept of 'better living through chemicals'.
- To investigate methods for limiting the intake of pro-inflammatory chemicals.
- To explore preventative strategies for cancer control through chemical exposure reduction.
Main Methods:
- Review of existing literature on chemical exposure and inflammation.
- Analysis of the role of environmental and dietary chemicals in cancer.
- Discussion of preventative measures and policy implications.
Main Results:
- The body of scientific evidence links chronic inflammation to increased cancer risk.
- Exposure to various pro-inflammatory chemicals is widespread and contributes to health issues.
- Reducing exposure to harmful chemicals presents a viable complementary strategy for cancer prevention.
Conclusions:
- Limiting pro-inflammatory chemical exposure is a crucial, yet often overlooked, aspect of cancer prevention.
- A proactive approach focusing on chemical intake reduction can complement pharmaceutical treatments.
- Further research and public health initiatives are needed to address chemical exposure and its link to cancer.
Related Concept Videos
01:26Peptic Ulcer Disease IV: Management
345
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
345
01:29Drugs for Treatment of Ulcerative Colitis in IBD
371
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
371
01:29Inflammatory Bowel Disease IV: Pharmacological Management
375
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
375
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
350
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
350
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
383
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
383
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
810
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
810